A study carried out by Chen et al. also found that for ER-positive and aromatase inhibitor-sensitive breast cancers, estrogen can bind to ER and further upregulate the c-MYC pathway to increase glutamine metabolism. Here, ESR1 is linked to breast carcinoma.